GRAL.US GRAIL, LLC
- Market cap
- USD 5.21B
- P/E
- -
- P/B
- 2.12x
- ROE
- -16.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GRAL.US undervalued?
Graham numberThe Graham number of GRAIL, LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GRAIL, LLC fundamental analysis
No fundamental analysis for GRAIL, LLC yet.
GRAIL, LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing,…
Full company profileGRAIL, LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GRAIL, LLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | - | 14.6M | 55.6M | 93.1M | 126M | 147M | 164M |
| Gross Profit | -14.1M | -10.3M | - | -100M | -116M | -95.6M | -78.0M | -62.6M | -14.8M |
| Operating Income | -287M | -256M | -316M | -1.27B | -5.44B | -1.52B | -2.19B | -534M | -606M |
| EBITDA | -269M | -243M | -309M | -1.21B | -588M | -638M | -610M | -378M | -421M |
| Net Income | -276M | -245M | -312M | -1.25B | -5.40B | -1.47B | -2.03B | -408M | -409M |
| EPS | -2.42 | -1.99 | -2.52 | -40 | -174 | -47 | -64 | -11 | -8.75 |
| Balance Sheet | |||||||||
| Total Assets | 687M | 636M | 706M | 9.74B | 5.60B | 4.56B | 2.98B | 2.92B | 2.73B |
| Total Liabilities | 86.5M | 85.0M | 144M | 307M | 956M | 911M | 480M | 344M | 277M |
| Shareholders' Equity | 600M | 551M | 562M | 9.43B | 4.65B | 3.65B | 2.50B | 2.58B | 2.45B |
| Cash & Short-term Investments | 641M | 544M | 583M | 221M | 242M | 97.3M | 763M | 904M | 789M |
| Total Debt | 2.53M | 42.0M | 63.0M | 111M | 96.0M | 84.4M | 68.1M | 98.0M | 85.8M |
| Cash Flow | |||||||||
| Operating Cash Flow | -209M | -246M | -232M | -688M | -561M | -596M | -577M | -299M | -323M |
| Capital Expenditure | 16.0M | 3.33M | 11.9M | 69.9M | 22.9M | 12.9M | 5.21M | 909K | 7.55M |
| Free Cash Flow | -225M | -249M | -244M | -758M | -584M | -609M | -582M | -300M | -331M |
| Ratios | |||||||||
| ROE | -45.9% | -44.5% | -55.6% | -13.2% | -116.2% | -40.2% | -81.0% | -15.8% | -16.7% |
| ROA | -40.1% | -38.5% | -44.2% | -12.8% | -96.4% | -32.2% | -67.9% | -14.0% | -15.0% |
| Net Profit Margin | - | - | - | -8,539.4% | -9,719.3% | -1,574.2% | -1,613.9% | -277.5% | -249.6% |
| Debt to Equity | 0.00x | 0.08x | 0.11x | 0.01x | 0.02x | 0.02x | 0.03x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GRAIL, LLC dividends
GRAIL, LLC has not paid dividends in the last 8 fiscal years.
Who owns GRAIL, LLC
- Insiders 5.06%
- Institutions 86.22%
- Public & others 8.72%
- Shares outstanding 45.0M
- Free float 34.6M
Top funds holding GRAL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PRIMECAP Odyssey Aggressive Growth | 1.58M | 3.53% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.30M | 2.91% | +5.71% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.05M | 2.35% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.05M | 2.34% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 452K | 1.01% | +0.14% | Aug 2026 |
| iShares Russell 2000 Value ETF | 388K | 0.87% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 328K | 0.73% | -0.41% | Oct 2026 |
| Vanguard US Opportunities Ins USD Acc | 254K | 0.57% | +0.63% | Sep 2026 |
| Vanguard Russell 2000 ETF | 240K | 0.54% | +1.13% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 237K | 0.53% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 205K | 0.46% | +28.58% | Sep 2026 |
| abrdn Healthcare Investors | 202K | 0.45% | 0.00% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 165K | 0.37% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 143K | 0.32% | +5.36% | Sep 2026 |
| Dimensional US Small Cap ETF | 138K | 0.31% | -0.02% | Oct 2026 |
| Morgan Stanley Inst Inception I | 132K | 0.29% | +5.56% | Jun 2026 |
| EQ/Morgan Stanley Small Cap Growth K | 126K | 0.28% | +3.10% | Sep 2026 |
| Vanguard Health Care ETF | 116K | 0.26% | +0.11% | Sep 2026 |
| DFA US Micro Cap I | 116K | 0.26% | +3.73% | Sep 2026 |
| T. Rowe Price New Horizons | 109K | 0.24% | 0.00% | Sep 2026 |
Top institutions holding GRAL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 4.16M | 9.30% | +27.90% | Jun 2026 |
| Baker Bros Advisors LP | 4.03M | 9.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.58M | 7.99% | +20.50% | Jun 2026 |
| Fort Hoosac Management, LLC | 3.10M | 6.93% | +199.91% | Jun 2026 |
| State Street Corp | 2.39M | 5.33% | +26.09% | Jun 2026 |
| PRIMECAP Management Company | 2.18M | 4.87% | +18.24% | Jun 2026 |
| Sessa Capital, L.P | 2.04M | 4.55% | +18.51% | Jun 2026 |
| Deep Track Capital, LP | 1.83M | 4.10% | +6.51% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.64M | 3.67% | +7.47% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.46M | 3.27% | -10.42% | Jun 2026 |
| Geode Capital Management, LLC | 991K | 2.22% | +19.74% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 749K | 1.67% | +10.26% | Sep 2026 |
| The Goldman Sachs Group Inc | 748K | 1.67% | +28.54% | Jun 2026 |
| Jefferies Financial Group Inc | 724K | 1.62% | +10.11% | Jun 2026 |
| Bank of America Corp | 723K | 1.62% | -20.86% | Jun 2026 |
| Casdin Capital, LLC | 480K | 1.07% | +108.70% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 478K | 1.07% | +42.72% | Jun 2026 |
| Northern Trust Corp | 373K | 0.83% | +6.72% | Jun 2026 |
| Citigroup Inc | 371K | 0.83% | +22.88% | Jun 2026 |
| Kingdon Capital Management LLC | 340K | 0.76% | 0.00% | Jun 2026 |
GRAIL, LLC company profile
- Company name
- GRAIL, LLC
- Ticker
- GRAL.US
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 910
- Fiscal year end
- December
- Address
- 250 S. Mathilda Avenue, Sunnyvale, CA, United States, 94086
- Phone
- (833) 694-2553
- Website
- grail.com
About GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.
GRAIL, LLC management
10- Dr. Joshua J. Ofman M.D., M.S.H.SCEO & Director · born 1965
- Mr. Aaron FreidinCFO & Head of Corporate Development · born 1979
- Mr. Robert P. RagusaAdvisor · born 1960
- Mr. Paul CiccolellaSenior Vice President of Global Development & Operations
- Dr. Satnam Alag Ph.D.Chief Technology Officer
- Sir Harpal S. Kumar M.A., M.B.A., MEngChief Scientific Officer and President of Global Clinical & Medical Affairs
- Mr. Abram Barth J.D., M.P.H.Chief Legal Officer & Corporate Secretary
- Ms. Trish RowlandSenior Vice President of Corporate Communications
- Ms. Alison HighlanderChief People Officer
- Mr. Andrew John PartridgeChief Growth Officer · born 1969